Clinical trials update from the American Heart Association: REPAIR‐AMI, ASTAMI, JELIS, MEGA, REVIVE‐II, SURVIVE, and PROACTIVE

[1]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[2]  J. McMurray,et al.  A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics , 2005, European journal of heart failure.

[3]  J. Cleland,et al.  Clinical trials update from the European Society of Cardiology meeting 2005: CARE‐HF extension study, ESSENTIAL, CIBIS‐III, S‐ICD, ISSUE‐2, STRIDE‐2, SOFA, IMAGINE, PREAMI, SIRIUS‐II and ACTIVE , 2005, European journal of heart failure.

[4]  M. Ballmaier,et al.  Haematopoietic stem cells improve cardiac function after infarction without permanent cardiac engraftment , 2005, European journal of heart failure.

[5]  H. Arnesen,et al.  Autologous stem cell transplantation in acute myocardial infarction: The ASTAMI randomized controlled trial. Intracoronary transplantation of autologous mononuclear bone marrow cells, study design and safety aspects , 2005, Scandinavian cardiovascular journal : SCJ.

[6]  L. Tavazzi,et al.  Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n‐3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure , 2004, European journal of heart failure.

[7]  N. Freemantle,et al.  Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING‐UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta‐analysis of cardiac resynchronisation therapy , 2004, European journal of heart failure.

[8]  N. Freemantle,et al.  Clinical trials update from the American Heart Association meeting: Ω‐3 fatty acids and arrhythmia risk in patients with an implantable defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PAD and DEFINITE , 2004, European journal of heart failure.

[9]  J. Cleland,et al.  Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure , 2004, Expert review of cardiovascular therapy.

[10]  M. Nieminen,et al.  Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). , 2002, European heart journal.

[11]  N. Freemantle,et al.  The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure—a meta‐regression analysis , 2002, European journal of heart failure.

[12]  J. Cleland,et al.  Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial , 2002, The Lancet.

[13]  J. Cleland,et al.  Levosimendan: a new era for inodilator therapy for heart failure? , 2002, Current opinion in cardiology.

[14]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[15]  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1987, The New England journal of medicine.